|
Opening remarks from the Chairman
Frank Borriello, CEO, Alloplex Biotherapeutics
|
09:00 - 09:05 |
|
Keynote: Mutations in the IL-7 receptor driving acute lymphoblastic leukemia
Scott Durum, Head, Cytokines and Immunity, NIH
|
09:05 - 09:40 |
|
Natural single domain antibodies as potential alternatives to monoclonal antibodies in the next generation immunotherapy
Rajesh Singh, Laboratory Director, Abzyme Therapeutics
|
09:40 - 10:15 |
|
Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immunomodulatory Targets
Tabb Sullivan, Senior Scientist, Project Leader, Integral Molecular
|
10:15 - 10:50 |
|
Morning Refreshments and Poster Presentations | One-to-One Networking Meetings
|
10:50 - 11:40 |
Targeted Antibodies and Combinations |
|
Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics
Rakesh Dixit, CEO, Bionavigen
|
11:40 - 12:15 |
|
Human Cell Culture: The Role of In Vitro models in Cancer Immunotherapy Development
Melissa Olekson, Scientific Support Specialist, PromoCell
|
12:15 - 12:50 |
|
Therapeutic targeting of the tumor microenvironment
|
12:25 - 12:55 |
|
ex vivo PBMC Activation of Antitumor Activity Offers Accelerated Path to Clinical Application
Frank Borriello, CEO, Alloplex Biotherapeutics
|
12:50 - 13:25 |
|
Lunch and Poster Presentations | One-to-One Networking Meetings
|
13:25 - 14:25 |
New Antibody Formats and Developments in CAR-T Cell Therapy |
|
Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta
Vicki Plaks, Translational Lead, Principal Scientist, Translational Sciences, Kite Pharma
|
14:25 - 15:00 |
|
Improving the Safety and Efficacy Profile of CAR-T: GM-CSF Neutralization with Lenzilumab
|
15:00 - 15:35 |
|
Next-generation gene editing technology for allogeneic T cell therapeutics
Megan van Overbeek, Associate Director of Functional Genomics, Caribou Biosciences
|
15:35 - 16:10 |
|
Evening Refreshments and Poster Presentations | One-to-One Networking Meetings
|
16:10 - 16:45 |
|
“RubrYc Therapeutics: Overcoming Immunodominance to Discover Next Gen Biotherapeutics”
Matt Greving, Co-Founder & VP, Technology, RubrYc Therapeutics Inc.
|
16:45 - 17:20 |
|
Closing remarks from the Chairman
|
17:20 - 17:25 |
|
Cocktail Reception | End of Day 1
|
17:30 - 17:35 |
|
Opening remarks from the Chairman
Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics
|
09:00 - 09:05 |
|
Keynote: Defining T Cell States Associated with Response to Combination Immunotherapy
Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics
|
09:05 - 09:40 |
|
Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors
William Williams, President, CEO, Briacell Therapeutics Corporation
|
09:40 - 10:15 |
|
Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models
Qingcong Lin, Senior Vice President, CEO, Biocytogen Boston Corporation
|
10:15 - 11:40 |
Pre-clinical & Translational Immuno-Oncology Developments |
|
Reversing trastuzumab resistance in HER2+ breast cancer
RJ Tesi, CEO, CMO, INmune Bio Inc.
|
11:40 - 12:15 |
|
Humanized Mouse Models for Immuno-Oncology Research
Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices
|
12:15 - 12:50 |
|
Preserving CTLA4 function to make a better and safer anti-CTLA4 antibody
Pan Zheng, Professor, University of Maryland School of Medicine
|
12:50 - 14:25 |
New Immune Checkpoints for Immunotherapy |
|
Clinical development of GITR based immunotherapies
Girish Naik, Medical Director, Leap Therapeutics
|
14:25 - 15:00 |
|
B cells in the human tumor microenvironment
Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh
|
15:35 - 16:05 |
|
Evening Refreshments and Poster Presentations | One-to-One Networking Meetings
|
16:05 - 16:55 |
|
Break out Session: Future of Biologics in Immune Checkpoint therapy
|
16:55 - 17:20 |
|
Closing remarks from the Chairman
|
17:20 - 17:25 |
|
.png)
.jpg){kind=logo}
